Visible Genetics cooperates with Virology Networks:
This article was originally published in Clinica
Visible Genetics and Utrecht, Netherlands-based Virology Networks have formed a joint venture, Visible Molecular Standards (VMS), to produce quality control and quantitative standards for identifying HIV, Hepatitis B and C, CMV and other infectious organisms. Visible Genetics, of Toronto, Canada, will contribute 35,000 shares and will finance the development of the joint venture. VMS will also set up a database of existing and new HIV genotypes, as well as their resistance to specific HIV drugs, in Europe and the US.
You may also be interested in...
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.